Abstract:HIV-1 based lentiviral viruses are considered powerful and versatile gene therapy vectors to deliver therapeutic genes to patients with hereditary or acquired diseases. These vectors can efficiently transduce a variety of cell types when dividing or non-dividing to provide permanent delivery and long-term gene expression. Demand for scalable manufacturing protocols able to generate enough high titre vector for widespread use of this technology is increasing and considerable efforts to improve vector production cost-effectively, is ongoing. Current methods for LV production mainly use transient transfection of producer cell lines. Cells can be grown at scale, either in 2D relying on culturing producer cells in multi-tray flask cell culture factories or in roller bottles or can be adapted to grow in 3D suspensions in large batch fermenters. This suits rapid production and testing of new vector constructs pre-clinically for their efficacy, particle titre and safety. In this study, we sought to improve lentiviral titre over time by testing two alternative commercially available transfection reagents Fugene® 6 and Genejuice® with the commonly used polycation, polyethyleneimine. Our aim was to identify less cytotoxic transfection reagents that could be used to generate LV particles at high titre past the often used 72 hour period when vector is usually collected before producer cell death is caused due to post transfection cytotoxicity. We show that LV could be produced in extended culture using Genejuice® and even by transfected cells in glass flasks in suspension. Because this delivery agent is less toxic to 293T producer cells, following optimisation of transfection we found that LV can be harvested for more than 10 days at high titre. Using our protocol, titres of 10 9 TU/ml and 10 8 TU/ml were routinely reached via traditional monolayer conditions or suspension cultures, respectively. We propose, this simple change in vector production enables large volumes of high titre vector to be produced, cost effectively for non-clinical in vivo and in vitro applications or for more stringent downstream clinical grade vector purification.

Efficient gene transfer mediated by HIV-1-based defective lentivector and inhibition of HIV-1 replication

[High-titer preparation of HIV-1-based defective lentivector and it mediated efficient gene transfer]

Lentiviral Delivery of Proteins for Genome Engineering

Progression and Application of HIV-1-derived Lentivectors

Transactivator and Structurally Optimized Inducible Lentiviral Vectors.

Efficient lentiviral transduction of different human and mouse cells

Lentiviral vectors with two independent internal promoters transfer high-level expression of multiple transgenes to human hematopoietic stem-progenitor cells.

A Single-Ltr HIV-1 Vector Optimized for Functional Genomics Applications

RNAi-inducing lentiviral vectors for anti-HIV-1 gene therapy

A Third-Generation Lentivirus Vector with a Conditional Packaging System

Optimization of lentiviral vectors generation for biomedical and clinical research purposes: contemporary trends in technology development and applications

Optimised protocols to generate high titre lentiviral vectors using a novel transfection agent enabling extended HEK293T culture following transient transfection and suspension culture

Robust and efficient regulation of transgene expression in vivo by improved tetracycline-dependent lentiviral vectors

Generation of a stable packaging cell line producing high-titer PPT-deleted integration-deficient lentiviral vectors

Lentiviral Delivery of RNAi Effectors Against HIV-1

Optimized protocol for high‐titer lentivirus production and transduction of primary fibroblasts

Delivering genes with human immunodeficiency virus-derived vehicles: still state-of-the-art after 25 years

High efficiency gene transfer to the central nervous system of rodents and primates using herpes virus vectors lacking functional ICP27 and ICP34.5

Optimization of a lentivirus-mediated gene therapy targeting HIV-1 RNA to eliminate HIV-1-infected cells

Superior lentiviral vectors designed for BSL-0 environment abolish vector mobilization

Lentivirus pre-packed with Cas9 protein for safer gene editing